Abstract
This review examines the potential applications of affibody molecules in various fields of biotechnology and clinical medicine. Consideration is given to the high affinity and specificity of affibody molecules for selected molecular targets, as well as their potential for the in vivo visualization of various malignant tumors. Significant attention is paid to preclinical and clinical studies of affibody conjugates with various radioisotopes for targeted radionuclide tumor imaging, which is particularly relevant in addressing challenges encountered during the diagnosis and treatment of these patients. Clinical trials demonstrate that radiopharmaceuticals are well-tolerated and effective for the assessment of tumor process prevalence and the determination of HER2/neu status in breast cancer patients, supporting further research.